Creating an effective platform for communication and exchange

The 2013 Annual Report of the Society for Neuro-Oncology

Society for NeuroOncology
This Annual Report covers the SNO 2013 fiscal year, from July 1st, 2012 through June 30, 2013.
Dear Colleagues and Friends,

As the outgoing President, I am happy to share with you some of the Society’s accomplishments and endeavors during my tenure. To begin with, SNO continues to grow with an overall increase in membership of 11% since October 2012, with current membership now approaching 1500 and representation from 42 countries.

I am likewise happy to share that the impact factor of the Society’s official journal, Neuro-Oncology, continues to rise, now standing at 6.1, solidifying its reputation as the leading journal in the field. Its success is, in large part, due to the dedication of the editor-in-chief, W K Alfred Yung who completes his successful tenure at the end of this year. Dr. Yung has set high-quality standards for the journal which I am certain the new editor-in-chief, Patrick Wen, will continue. I also look forward to the publication of our new journal, Neuro-Oncology Practice, which will be edited by Dr. Susan Chang with the support of an editorial board comprised of internationally respected experts from a range of disciplines.

Our Society stands today on the threshold of dramatic new discoveries in the field of neuro-oncology. So that SNO is well positioned to meet the challenges that lie ahead, a group of key SNO members representing a range of disciplines participated in a two-day retreat with a goal of charting a course for next chapter in our organization’s evolution. This effort resulted in a forward-looking strategic plan that I believe will be our roadmap to achieving our organizational objectives over the next five years. I am excited that President-elect David Reardon will take the helm to work on these initiatives in an effort to make SNO serve its membership in the best way possible.

I would like to acknowledge some of the individuals who have contributed to the success of our Society and by extension furthered the development of neuro-oncology as a field. First, much appreciation goes to SNO Foundation members Mark Gilbert (chair), Mitchel Berger, Susan Chang and Victor Levin and members of the Partners Advisory Council for their continued support and guidance as the Society continues to grow. I would also like to recognize the members of the Board of Directors for their willingness to represent the diverse disciplines of the neuro-oncology community and for their input into critical aspects of operating the Society.

Thanks go to Jan Esenwein, Linda Greer, Megan Bell and Kristin Odom for their administrative support, and especially to Chas Haynes for his outstanding leadership. This team provides the continuity needed to allow smooth transitions between leadership periods and maintains a cohesive infrastructure for the Society.

As I finish my term, I thank all the members of SNO for your support throughout the past two years. I remain confident that SNO will continue to lead the way and provide a model of cooperation that will ultimately result in improved outcome and quality of life for patients with CNS tumors.

Sincerely,

Kenneth Aldape, MD
SNO President
Dear Society Members,

It is with great pleasure that I submit this 2013 Annual Report to the members and friends of the Society for Neuro-Oncology. As you read through the pages of this Report, I hope you will agree that much has been accomplished in the last twelve months and that many exciting opportunities lie ahead.

The Society thanks Kenneth Aldape for his thoughtful and steady leadership during his tenure as President. In addition to presiding over a period of unprecedented growth both in terms of membership and attendance at our annual meeting, Dr. Aldape instituted a strategic planning process that is helping to guide the next phase of our organization’s evolution. As a result of Dr. Aldape’s efforts, our incoming President, David Reardon, takes the reigns of a dynamic organization that is focused on adding value to its members.

We continue to seek out meaningful opportunities for collaboration with other organizations with similar goals. To that end, we partnered with the Section on Tumors on a special meningioma satellite meeting, held jointly organized educational sessions with the American Academy of Neurology at our respective meetings, and organized special SNO sessions at the annual meetings of the Asian Society for Neuro-Oncology and European Association of Neuro-Oncology. We also joined with the Pediatric Brain Tumor Foundation and the National Brain Tumor Society on several important initiatives to advance basic and translational pediatric research.

This year has been an exceptional year for our flagship journal, Neuro-Oncology. Under the editorial care of Editor in Chief W K Alfred Yung, the journal remains not only the seminal publication in the field of neuro-oncology, but one of the top ranked oncology titles in the world. The Society is confident that Patrick Wen, who assumes the leadership of the journal in January of 2014, will continue this positive trajectory and build on Dr. Yung’s significant accomplishments.

Looking ahead, the Society is excited to announce a partnership with Oxford University Press to launch a second journal, entitled Neuro-Oncology Practice, in the first quarter of 2014. We expect this new publication to become an important resource on clinical best practices and patient care through which readers will learn of the latest developments in clinical decision-making, molecular profiling, advanced imaging, symptom management, quality of life, psychosocial support and a range of other important topics on the applied and practical aspects of neuro-oncology. Edited by Susan Chang, the title will be published initially on a quarterly basis, and will be included as a value added benefit of membership in the Society.

Thanks to the efforts of our volunteer leadership, dedicated members and partner organizations, the Society for Neuro-Oncology stands ready to support the work of those on the frontlines of neuro-oncology clinical care and research. I would like to acknowledge Jan Esenwein, Linda Greer, Megan Bell and Kristin Odom for their tireless efforts on behalf of the Society. In closing, it has been a highly productive and positive year for our Society, and it is therefore with confidence and optimism that we approach the challenges that ahead.

J. Charles Haynes, JD
SNO Executive Director
Dear Society for Neuro-Oncology Members and Supporters,

On behalf of the SNO Foundation, I am pleased to report on the activities of your Foundation over the past year.

As the fundraising arm of SNO, the Foundation partners with the Society to support educational resources to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

The support of our corporate and nonprofit partners, as well as the generosity of our members, allows us to maintain the editorial office of Neuro-Oncology, the SNO administrative office, SNO's international outreach efforts, as well as the costs associated with the SNO annual meeting, research awards and initiatives for young investigators.

Thanks to your generosity, this year the Foundation was able to make several strategic investments back into the field. These included financial support for:

- A webcast of “SNO Highlights” from the annual meeting
- The Society’s first ever town-hall style meeting
- Twelve meeting travel scholarships selected through a competitive application process
- Sponsorship of the abstract supplement for the Pediatric Basic Science Conference
- Improvements in the audio-visual systems for the annual meeting

Most significantly, as you will read further in this Annual Report, our Society is about to embark on a very exciting initiative to publish a companion journal to our flagship publication, Neuro-Oncology. With support of the National Brain Tumor Society, the Foundation is pleased to provide the seed-money needed to launch Neuro-Oncology Practice.

To fund the types of efforts like the new journal that will truly have an impact on the future of our field, the Foundation relies on the support of our corporate and foundation partners as well as individual society members. The non-profit associations, foundations and societies, and corporate donors who support the annual meeting at the highest level with a multi-year commitment are members of the Partner’s Advisory Council, which has direct access to the SNO Board of Directors and Foundation Executive Board on a regular basis. The 2013 members of the Council include the Genentech, the National Brain Tumor Society, Merck, the Pediatric Brain Tumor Foundation, and the Sontag Foundation. This year we are pleased to welcome Novocure as our newest Advisory Council member.

The SNO Foundation remains committed to supporting important new initiatives and we continue to look ahead for additional opportunities to realize our common mission – finding a cure for brain tumors.

Very truly yours,

Mark R. Gilbert, MD (Foundation President)
Mitchel S. Berger, MD
Susan M. Chang, MD
Victor A. Levin, MD
The 17th Annual Scientific Meeting of the Society for Neuro-Oncology was held November 15–18, 2012, in Washington, D.C. SNO thanks E. Antonio Chiocca (Scientific Chair), Balveen Kaur and Vinay Puduvalli (Education Day Co-Chairs), and Michael Glantz (Quality of Life Chair), for composing a comprehensive program highlighting cutting-edge laboratory and clinical research in the field of neuro-oncology. The meeting resulted in a stimulating exchange of ideas among neuro-oncologists, medical oncologists, neurosurgeons, neuropathologists, radiation oncologists, neuroradiologists, pediatricians, laboratory scientists, nurses and other specialists involved in the research, diagnosis, care and treatment of patients with tumors of the central nervous system. In addition to the thought-provoking Education Day and the abstract driven scientific sessions of the main meeting, SNO offered a number of innovative features at the 2012 meeting, including a special biomarkers course, a keynote address from Bert Vogelstein, a new Public Service Award, the inaugural Abhijit Guha Award and Lecture, expanded sessions for Young Investigators, and an evening satellite symposium on 1p/19q codeleted anaplastic gliomas.

Education Day
The meeting began on Thursday, November 15th with an opportune and relevant program for the Education Day consisting of concurrent morning sessions entitled Targeted Therapies Against Primary Brain Tumors and Quality of Life / Symptom Management. The afternoon session offered a novel program titled SNO Course on the Basics of Biomarkers.

SNO Annual Meeting
The formal meeting launched on Friday November 16th with Sunrise Sessions on the following topics: 1) EANO and SNO Joint Session: From Guidelines to New Trials in Low Grade Gliomas: The American and European Views; 2) NF2 Update: Hearing Restoration and Foundations for the Future; 3) Energetics and Metabolism; 4) Re-engineered T Cells and Bone Marrow Cells. The first plenary session began with an official meeting welcome by Dr. Chiocca followed by a Public Service Award presented to Edward Shaw and by presentation of top-Scoring Abstracts.

Subsequent to these events the first Abhijit Guha Award was bestowed to James Rutka, and we heard an invigorating keynote lecture given by Bert Vogelstein.

A Young Investigators Luncheon Roundtable was held at noon on Friday at which trainees and early phase independent investigators participated in informal discussions with senior investigators at roundtables organized into a variety of different areas. Afternoon concurrent sessions included: 1) Medical, Neuro- and Radiation Oncology and 2) Basic Sciences. The next set of concurrent sessions included 1) Symptom Management, Neuro-cognitive and Quality of Life, and 2) Molecular Epidemiology, -Omics and Prognostic Markers. After an exciting, first of its kind, town-hall style meeting on the management of 1p/19q co-deleted anaplastic gliomas, the evening opened for poster sessions, which was an opportunity for lively discussion and debate.

Saturday, November 17th Sunrise Sessions featured the following topics: 1) Asian Society for Neuro-Oncology Session; 2) CMV and Glioma Connection; 3) Mechanisms of Glioblastoma Immuno-evasion; 4) Pituitary Tumors: Biology and Treatment. Next in line was the presentation of the Victor Levin Award and Lecture by Gregory Cairncross and Robert Jenkins. The first afternoon concurrent sessions were 1) Cell Biology/Signaling and Epidemiology or 2) Pathology and Radiology with subsequent afternoon concurrent sessions on 1) Angiogenesis/Invasion and 2) Surgery and Immunology. The second lively poster session took place after the oral sessions concluded for the day. That evening, the SNO Banquet beheld itself as the social highlight of the meeting.

Sunday, November 18th witnessed the first SNO highlights session—an invitation only press program that highlighted new advances in neuro-oncology, major trial results, and significant advances in supportive care and patient quality of life. Sunrise Sessions included: 1) Oncolytic Viruses: Clinical Trials Update; 2) The Radiobiology of CNS Tumors; 3) The Biology of Brain Metastases; and 4) MicroRNA Biology in CNS Tumors. These were followed by a plenary session presenting Top Scoring Abstracts and a RANO session prior to the meeting adjournment.
Abstract Award Winners

**Sebastian Bender**
Award for Excellence in Pediatric Basic Science
Supported by the Pediatric Brain Tumor Foundation
*Molecular characterization of mutated histone in pediatric glioblastoma*

**Justin Lathia**
Award for Adult Basic Science
Supported by the National Brain Tumor Society
*Know thy enemy: the development of imaging models to interrogate the complexity of cancer stem cells in malignant brain tumors*

**Olivier Chinot**
Award for Adult Clinical Research
*Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio*

**Jonathan L. Finlay**
Award for Pediatric Clinical Research
*Final Report of Outcome of the CCG-99703 Children’s Oncology Group Study for Children Less Than 3 Years of Age Newly-Diagnosed with Malignant Brain Tumors*

**Rakesh Jalali**
Award for Quality of Life
Supported by the Sontag Foundation
*Hippocampus as a dose constraint model to preserve neurocognition in young patients with low-grade brain tumors treated with focal stereotactic conformal radiotherapy: data from a prospective clinical trial*

**Robert B. Jenkins**
Award for Excellence in Epidemiology
Supported by EMD Serono
*New low frequency risk loci in the 8q24.21 (CCDC26) region are strongly associated with risk of oligodendrogliomas and IDH1/2 mutated astrocytomas*

**Ralf S. Schmid**
Award for Excellence in Adult Basic Science
Supported by Genentech
*Cortical GFAP+ astrocytes as a potential cellular origin of GBM*

**Shih-Shan Lang**
Award for Excellence in Pediatric Translational Science
Supported by the Pediatric Brain Tumor Foundation
*Development of pediatric glioma models for BRAF-targeted therapy*

**Michael Weller**
Award for Adult Clinical Research
*MGMT promoter methylation predicts benefit from temozolomide versus radiotherapy in malignant astrocytomas in the elderly*

**Gelareh Zadeh**
Award for Excellence in Adult Translational Research
Supported by Merck, Inc.
*Spatiotemporal regulation of GBM neo-vascularization and response to therapy*

Edward Shaw (L) was recognized at the opening of the meeting as the inaugural recipient of the SNO Public Service Award, presented to him by meeting chair E. Antonio Chiocca (R) for his many years of service to the Society and his support of SNO’s mission.

Gregory Cairncross (L) and Robert Jenkins (C) received the Levin Award from SNO President Kenneth Aldape (R), and delivered a joint presentation entitled Science, Medicine and Oligodendroglioma.

James Rutka delivered the inaugural Abhibit Guha Award and Lecture entitled Glioblastoma Invasion, Advances from the Leading Edge. SNO was honored to host the Guha family who were present for the lecture. Shown from left to right: Deep Guha, Soma Guha, Tanya Guha, James Rutka, and Frederick Lang.

Bert Vogelstein (L) delivered an invigorating Keynote Address entitled Cancer Genomes and their Implications for Research and Practice, and received a plaque from meeting chair E. Antonio Chiocca (R).
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, experienced yet another year of unprecedented success in its effort to help SNO meet its goal of advancing multidisciplinary research and education in neuro-oncology. It is also approaching significant changes, as Patrick Wen at Dana-Farber Cancer Institute will take on the role of Editor-in-Chief in 2014.

Record High Impact Factor
The editors and staff are thrilled to announce that Neuro-Oncology’s impact factor for 2012 is 6.180, a record high (Figure 1). Of note, the journal’s only direct competitor received a score of 3.115. Neuro-Oncology is now ranked 24 of 196 oncology journals and 10 of 192 clinical neurology journals.

Increase in Submitted and Published Articles
The journal experienced a continued increase in the number of new submissions in 2013. The editors—Editor-in-Chief W. K. Alfred Yung, SNO Executive Editor C. David James, JSNO Executive Editor Ryo Nishikawa, and EANO Executive Editor Michael Weller—will have acted on a projected 991 new and revised manuscripts by the end of 2013 (Table 1), an increase over the previous year. From January 1 through September 30, 146 papers were accepted for publication. The journal’s acceptance rate is approximately 20%, which demonstrates a continued dedication to publishing only the most significant research, even as the number of submissions increase.

Through the October issue, Neuro-Oncology had published 144 articles in 1452 pages (versus 129 in 1313 pages as of October 2012), demonstrating continued growth. The journal also published the abstracts of the International Symposium on Pediatric Neuro-Oncology, the British Neuro-Oncology Society and of course SNO. The journal also published its first supplemental issue, which was edited by Susan Chang and addressed the applied and practical aspects of neuro-oncology.

As of September 30, Neuro-Oncology had received manuscripts from 39 countries—38% from the United States and Canada, 36% from Europe, and 21% from Asia. Approximately half of all accepted papers were from the United States and Canada.

Neuro-Oncology appoints new Editor-in-Chief
Patrick Wen has been appointed as the new Editor-in-Chief of the Society’s flagship journal, Neuro-Oncology. Dr. Wen is Professor of Neurology at Harvard Medical School and Director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center in Boston, Massachusetts. He was formerly Vice President of SNO and is currently Chair of the Neuro-oncology Section of the American Academy of Neurology. His research focuses on novel therapeutics for brain tumours and optimizing response assessment and trial designs.

Dr. Wen takes the reins of a publication that has gone from strength to strength under the leadership of W. K. Alfred Yung who was appointed Editor-in-Chief of Neuro-Oncology in 2007. During Dr. Yung’s tenure, the journal increased in frequency from four to six issues per year, and then again to twelve issues per year. In addition, Dr. Yung guided the journal’s Impact Factor to an impressive 6.180, which puts Neuro-Oncology among the world’s top oncology and neurology titles.

Professor Wen looks forward to working with the European Association of Neuro-Oncology (EANO), and the Japanese Society for Neuro-Oncology (JSNO) to build on the wonderful legacy of Dr. Yung, in making Neuro-Oncology the foremost journal in the field and advancing our mission of developing better treatments and improving the quality of life of brain tumour patients and patients with neurologic complications of cancer.
Peer & Statistical Reviewers

*Neuro-Oncology* is indebted to the members of its editorial board (whose names appear in every issue of the journal) and its numerous peer and statistical reviewers, all of whom have helped the journal along its path to success. Listed below are those reviewers who had conducted manuscript reviews as of September 30. The staff apologizes for any inadvertent omissions.

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013 (through Sept. 30, 2013) (projected end of year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>411</td>
<td>454</td>
<td>669</td>
<td>527 (704)</td>
</tr>
<tr>
<td>Revised</td>
<td>153</td>
<td>217</td>
<td>244</td>
<td>215 (287)</td>
</tr>
<tr>
<td>Total</td>
<td>564</td>
<td>671</td>
<td>913</td>
<td>742 (991)</td>
</tr>
</tbody>
</table>

Table 1. Number of new and revised manuscripts submitted

**Figure 1. Neuro-Oncology’s impact factors.** The impact factor, published annually by Thomson Scientific in the Journal Citation Reports, is determined using article citation rates and is used to measure journal quality.
As part of our ongoing effort to better understand CNS malignancies and bring new perspectives to the field, SNO strives to reach out and collaborate with sister groups that share our scientific mission. Highlights of these interorganizational efforts are described below.

**Pediatric Neuro-Oncology Basic and Translational Research Conference**

The 2nd Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference took place in Fort Lauderdale on May 16-17, 2013, at the Hyatt Pier 66 Hotel. The meeting was supported with a grant from the Pediatric Brain Tumor Foundation (PBTF), and organized by the Society for Neuro-Oncology. SNO and PBTF thank James Rutka for serving as the scientific chair this very successful event.

More than 270 clinicians, scientists, research students, and post-doctoral fellows participated in the conference. There was representation from more than 15 countries with some of the more distant sites of origin being China, Australia, and Japan.

Over a packed two day period, attendees learned of the latest developments in pediatric basic science and translational therapeutics, covering medulloblastoma, ependymoma, high grade glioma and diffuse intrinsic pontine glioma. Plans are already underway for the next conference devoted therapeutic strategies to benefit children with these aggressive cancers. Abstracts of the original research submitted to the conference were published in the Society’s journal, *Neuro-Oncology*.

**Multidisciplinary Management of Meningioma Symposium**

SNO partnered with the Section on Tumors (SOT) of the AANS/CNS to collaboratively develop a one-day symposium dedicated to the multidisciplinary management of meningiomas. The symposium, which was held on April 27, 2013, in New Orleans, was developed by Patrick Wen (SNO), Leland Rogers (SNO) and Michael Vogelbaum (SNO and SOT). The symposium covered all aspects of meningioma including recent advances in pathology, imaging, biology, treatment options, and clinical investigation.

Highlights of the invited speaker program included discussions of recent advances in understanding the genetics and grading of meningiomas, a review of new murine models for studying the pathobiology of meningiomas, an insightful evaluation of the longterm risk of recurrence and its relation to extent of resection, discussions of radiation therapy and radiosurgery and discussions of new investigational therapies. In addition, there were oral presentations of original science competitively selected from abstract submissions addressing a wide range of topics, including new genes associated with the development of meningiomas, mTOR inhibitors, a novel immunotherapy, development of murine models and novel imaging methods for discriminating between grades of meningioma.

**19th Annual Neuro-Tumor Club Dinner Meeting**

The 19th Annual Neuro-Tumor Club Dinner Meeting took place on April 8, 2013, at the Washington Plaza Hotel in Washington, DC. This meeting, for brain tumor researchers attending the annual meeting of the American Association of Cancer Researchers (AACR), was organized by the Society for Neuro-Oncology with the support of Genentech, Merck and the National Brain Tumor Society. The event drew approximately 200 investigators from diverse disciplines relevant to brain tumor research, and was very successful in strengthening existing personal research connections and collaborations, generating new associations and presenting the group with updates in topics important to brain tumor research.

The talks, selected through a competitive application process, were arranged in four consecutive sessions encompassing a range of important topic areas including animal models, biomarkers, stem cells, CNS metastases, personalized combinatorial therapy and immunotherapy. SNO thanks John Park and Raymund Yong for chairing this stimulating and thought-provoking meeting.
SNO TO PUBLISH NEW JOURNAL

Oxford University Press and SNO are pleased to announce that they will be publishing a new journal, Neuro-Oncology Practice, beginning in 2014. The new journal will be edited Dr. Susan Chang, Director of the Division of Neuro-Oncology at UCSF, in San Francisco, California, USA.

The field of neuro-oncology focuses on the research and treatment of brain and spinal tumours. Neuro-Oncology Practice will cover applied neuro-oncology, filling a need for practical and educational content. This new journal will also provide the multidisciplinary field of neuro-oncology professionals, such as physicians, nurses, physical and occupational therapists, palliative care specialists, and neuropsychologists, with clinical information to enhance patient care, quality of life, psycho-social support, and management of co-morbid conditions.

Some of the aims of Neuro-Oncology Practice include:

• To apply new trial results to improve standards of patient care,
• To translate scientific advances, such as tumour molecular profiling and advanced imaging, into clinical treatment decision-making and personalized brain tumour therapies, and
• To raise awareness of basic, translational, and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues, and caregiving.

Neuro-Oncology Practice will be the sister journal to Neuro-Oncology, SNO's official journal, which Oxford has published since 2010.

The launch of this new title was made possible by a generous grant from the National Brain Tumor Society.

The editorial structure of Neuro-Oncology Practice will mirror that of Neuro-Oncology, with representation from SNO’s sister societies in Europe and Asia.

Susan Chang
Editor-in-Chief

Rakesh Jalali
ASNO Editor

Wolfgang Grisold
EANO Editor

Jeffrey Wefel
SNO Editor

Susan Chang will serve as the Editor-in-Chief of the new title that SNO will be publishing with Oxford University Press.
Society For Neuro-Oncology

Financial Highlights
Fiscal Year Ended June 30, 2012

The following financial highlights are prepared by management of Society for Neuro-Oncology for the fiscal year ended June 30, 2012 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2012

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,240,000</td>
</tr>
<tr>
<td>Investments</td>
<td>$564,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>$48,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>$156,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$2,008,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$257,000</td>
</tr>
<tr>
<td>Net assets</td>
<td>$1,751,000</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$2,008,000</strong></td>
</tr>
</tbody>
</table>

Statement of Activities highlights, for the fiscal year ended June 30, 2012

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$1,821,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>$1,385,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$436,000</strong></td>
</tr>
</tbody>
</table>
Society For Neuro-Oncology

Financial Highlights
Fiscal Year Ended June 30, 2013

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2013 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2013

<table>
<thead>
<tr>
<th>Cash and cash equivalents</th>
<th>$ 1,400,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments</td>
<td>676,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>25,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>178,000</td>
</tr>
<tr>
<td>Other assets</td>
<td>65,000</td>
</tr>
</tbody>
</table>

**Total assets**

$ 2,365,000

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>$ 229,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets</td>
<td>2,136,000</td>
</tr>
</tbody>
</table>

**Total liabilities and net assets**

$ 2,365,000

Statement of Activities highlights, for the fiscal year ended June 30, 2013

<table>
<thead>
<tr>
<th>Total revenues and other support</th>
<th>$ 2,103,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total program and supporting service expenses</td>
<td>1,888,000</td>
</tr>
</tbody>
</table>

**Change in net assets**

$ 215,000
Executive Director
J. Charles (Chas) Haynes, J.D.

Chief Administrative Officer
Jan Esenwein

Membership Manager
Linda Greer

Administrative Coordinator
Megan Bell

Communications Coordinator
Kristin Odom
OFFICERS, BOARD OF DIRECTORS AND COMMITTEES

President
Kenneth Aldape, MD

Vice President
Michael Vogelbaum, MD, PhD

Secretary-Treasurer
E. Antonio Chiocca, MD, PhD

Board of Directors
Eric Bouffet, MD
Sherry Fox, PhD
Mary Lovely, PhD
Andrew Parsa, MD
David Peereboom, MD
Russell Pieper, PhD
David Reardon, MD
Jann Sarkaria, MD
Michael Taylor, MD, PhD

Past President
Frederick Lang, MD

Foundation Board
Mark R. Gilbert, MD (President)
Victor A. Levin, MD (SNO Founder)
Mitchel S. Berger, MD
Susan Chang, MD

Journal Editor in Chief
W. K. Alfred Yung, MD

Journal Executive Editor (SNO)
C. David James, PhD

SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society’s financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: David Eisenstat

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: Thomas Mikkelsen

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society’s official journal and the Society’s newsletter, and will have the responsibility of advising the Board of Directors on the Society’s internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: Nicholas Butowski

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Co-Chairs: Jonathan Knisely and Mark Gilbert
The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

*Chair: Eric Bouffet*

The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President.

*Chair: Antonio Chiocca*

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member's professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

*Chair: Manmeet Ahluwalia*

The Website Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society's official website. The Website Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

*Chair: Erik Sulman*

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

*Chair: Jason Huse*
SNO SUPPORTERS
Through 2013 Fiscal Year Ending June 31, 2013

**Platinum Level**
Genentech
Merck
Novocure
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Sontag Foundation

**Benefactors**
CERN Foundation

**Supporters**
American Brain Tumor Association
Brain Tumour Foundation of Canada
Celldex Therapeutics
Chris Elliott Foundation
Northwest Biotherapeutics

**International Outreach & Guha Fund**
Children's Brain Tumor Foundation
Ali Choucair
Takamitsu Fujimaki
Sontag Foundation
Victor Levin Founders Society

**Individual Donations and Levin Society**
Wallace Gleason & Family  
*in memory of Maryjo Gleason*
Carol S Gold
Victor and Ellen Levin
Claudia Schlimper
Michael Young  
*in memory of William Priestman Thorpe IV*

**Exhibitors**
American Brain Tumor Association
Arbor Pharmaceuticals
Castle Bioscience
Celldex
Central Nervous System Tumor Education Foundation
CERN Foundation
Chris Elliott Foundation and Musella Foundation
Del Mar
EANO
Elekta
Foundation Medicine, Inc.
Genentech
International Brain Tumour Association
IsoRay Medical
LabCorp
Leica Microsystems
Magforce AG
Medical Advocates
Monteris Medical
National Brain Tumor Society
Nicki Leach Foundation
Northwest Biotherapeutics, Inc.
Novocure
Oxford University Press
Pediatric Brain Tumor Foundation
Sigma Tau
Tocagen

SNO mourns the loss of the following members:
Gregory Foltz
John Ohlfest

Through 2013 Fiscal Year Ending June 31, 2013
Mission
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

Vision
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

SNO Members

- Neuro-oncology 31%
- Radiation Oncology 10%
- Basic Science 10%
- Pathology 6%
- Medical Oncology 7%
- Radiology 1%
- Psychology 1%
- Pharmacology 1%
- Epidemiology 1%
- Statistics 1%
- Public Health 1%
- Foundation 1%
- Industry 3%
- Other 5%
- Neurosurgery 21%
Creating an effective platform for communication and exchange

The 2013 Annual Report of the Society for Neuro-Oncology

NETWORKING
COLLABORATION
INTERCHANGE
KNOWLEDGE
COMMUNICATION
ADVANCEMENT